

FILE 'HOME' ENTERED AT 15:49:00 ON 27 SEP 2006

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 15:49:23 ON 27 SEP 2006

68 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> fusion and TOLAIII

3	FILE BIOSIS
1	FILE BIOTECHABS
1	FILE BIOTECHDS
2	FILE BIOTECHNO
4	FILE CAPLUS
66	FILE DGENE
1	FILE EMBASE
3	FILE ES BIOBASE

35 FILES SEARCHED...

1	FILE IFIPAT
1	FILE LIFESCI
4	FILE MEDLINE
3	FILE SCISEARCH
3	FILE TOXCENTER
2	FILE USPATFULL
1	FILE WPIDS
1	FILE WPINDEX

16 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX

L1 QUE FUSION AND TOLAIII

=> d rank

F1	66	DGENE
F2	4	CAPLUS
F3	4	MEDLINE
F4	3	BIOSIS
F5	3	ES BIOBASE
F6	3	SCISEARCH
F7	3	TOXCENTER
F8	2	BIOTECHNO
F9	2	USPATFULL
F10	1	BIOTECHABS
F11	1	BIOTECHDS
F12	1	EMBASE
F13	1	IFIPAT
F14	1	LIFESCI
F15	1	WPIDS
F16	1	WPINDEX

=> file caplus medline biosis toxcenter biotechno biotechabs

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1.83	2.04

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:51:12 ON 27 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 15:51:12 ON 27 SEP 2006

FILE 'BIOSIS' ENTERED AT 15:51:12 ON 27 SEP 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'TOXCENTER' ENTERED AT 15:51:12 ON 27 SEP 2006
COPYRIGHT (C) 2006 ACS

FILE 'BIOTECHNO' ENTERED AT 15:51:12 ON 27 SEP 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

=> fusion and TolAIII
L2 16 FUSION AND TolAIII

=> dup remove
ENTER L# LIST OR (END):12
PROCESSING COMPLETED FOR L2
L3 5 DUP REMOVE L2 (11 DUPLICATES REMOVED)

=> d ti 1-5

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
TI Solution Structure of the E.coli TolA C-terminal Domain Reveals
Conformational Changes upon Binding to the Phage g3p N-terminal Domain

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of Escherichia TolA domain for production and purification of
recombinant fusion proteins

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
TI Expression of proteins using the third domain of the Escherichia coli
periplasmic-protein TolA as a fusion partner

L3 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 3
TI The Tol/Pal system function requires an interaction between the C-terminal
domain of TolA and the N-terminal domain of TolB.

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4
TI TolAIII co-overexpression facilitates the recovery of
periplasmic recombinant proteins into the growth medium of Escherichia
coli

=> d ab bib 1-5

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
AB The Tol-Pal system of Escherichia coli is a macromol. complex located in
the cell envelope. It is involved in maintaining the integrity of the
outer membrane and is required for the uptake of two different types of
macromols., which are bacteriotoxins (colicins) and DNA of filamentous
bacteriophages. The TolA protein plays a central role in these import
mechanisms. Its C-terminal domain (TolAIII) is involved in the
translocation step via direct interaction with the N-terminal domain of
colicins and the N-terminal domain of the phage minor coat gene 3 protein
(g3pN1). Extreme behaviors of TolAIII have been previously
observed, since the structure of TolAIII either remained unaffected

or adopted disordered conformation upon binding to different pore-forming colicins. Here, we have solved the 3D structure of free TolAIII by heteronuclear NMR spectroscopy and compared it to the crystal structure of TolAIII bound to g3pN1 in order to study the effect of g3pN1 on the tertiary structure of TolAIII. Backbone 1H, 15N and 13C resonances of the g3pN1-bound TolAIII were also assigned and used to superimpose the solution structure of free TolAIII on the crystal structure of the g3pN1-TolAIII fusion protein. This allowed us to track conformational changes of TolAIII upon binding. While the global fold of free TolAIII is mainly identical to that of g3pN1-bound TolAIII, shift of secondary structures does occur. Thus, TolAIII, which interacts also in vivo with Pal and TolB, is able to adapt its conformation upon binding to various partners. Possible models for protein binding mechanisms are discussed to explain this so-far unobserved behavior of TolAIII.

AN 2005:115822 CAPLUS
 DN 142:331498
 TI Solution Structure of the E.coli TolA C-terminal Domain Reveals Conformational Changes upon Binding to the Phage g3p N-terminal Domain
 AU Deprez, Christophe; Lloubes, Roland; Gavioli, Marthe; Marion, Dominique; Guerlesquin, Françoise; Blanchard, Laurence
 CS Laboratoire de Résonance Magnétique Nucléaire, Institut de Biologie Structurale Jean-Pierre Ebel (CNRS-CEA-UJF), UMR 5075, Grenoble, 38027, Fr.
 SO Journal of Molecular Biology (2005), 346(4), 1047-1057
 CODEN: JMOBAK; ISSN: 0022-2836
 PB Elsevier B.V.
 DT Journal
 LA English
 RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 AB The present invention relates to fusion proteins, particularly for use in expression and/or purification systems. The present inventors have found that the TolAIII domain has remarkable properties which are of particular use as a fusion protein partner to achieve high levels of expression in a host cell. In one aspect of the invention, a TolAIII domain or a functional homolog, fragment, or derivative thereof is located towards the N-terminus of the fusion polypeptide and a non-TolA polypeptide is located towards the C-terminus of the fusion polypeptide. Thus, numerous proteins were produced with recombinant E. coli as fusions with E. coli TolA domain III, e.g., large amts. of BCL-XL protein were prepared For this purpose, three different expression plasmids were created: pTolE, pTolX, and pTolT. These plasmids are used to produce fusion proteins which may be cleaved with enterokinase, factor Xa, or thrombin, resp., to produce the desired protein.

AN 2003:551526 CAPLUS
 DN 139:112735
 TI Use of Escherichia TolA domain for production and purification of recombinant fusion proteins
 IN Gokce, Isa; Anderluh, Gregor; Lakey, Jeremy Hugh
 PA Newcastle University Ventures Limited, UK
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057708	A2	20030717	WO 2003-GB78	20030110
	WO 2003057708	A3	20031231		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2472328 AA 20030717 CA 2003-2472328 20030110
AU 2003202005 A1 20030724 AU 2003-202005 20030110
EP 1465999 A2 20041013 EP 2003-700857 20030110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005514028 T2 20050519 JP 2003-558022 20030110
US 2005130269 A1 20050616 US 2003-501071 20030110
PRAI GB 2002-689 A 20020110
WO 2003-GB78 W 20030110

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

AB The third domain of the periplasmic protein TolA from Escherichia coli (TolAIII) was used as a fusion partner in the expression of various proteins from bacteria and eukaryotes. TolAIII is small domain, expressed in high yields as a soluble protein in the cytoplasm of E. coli. Proteins were linked to the C-terminus of TolAIII by a short flexible linker containing sites for endopeptidases. Three different vectors were prepared, containing sites for enterokinase, thrombin or factor Xa. Fusion proteins also contain a His6-Ser2 tag at their N-terminus for easier purification. Up to 90 mg fusion protein per L bacterial culture was obtained using these vectors. Colicin N R-domain was expressed with this system as a fusion and processed further for functional studies. The yield of final pure R-domain was doubled as compared to the direct expression. The system may prove to be useful in the preparation of other peptides and proteins.

AN 2003:206520 CAPLUS

DN 140:13544

TI Expression of proteins using the third domain of the Escherichia coli periplasmic-protein TolA as a fusion partner

AU Anderluh, Gregor; Gokce, Isa; Lakey, Jeremy H.

CS Department of Biology, University of Ljubljana, Ljubljana, 1000, Slovenia

SO Protein Expression and Purification (2003), 28(1), 173-181

CODEN: PEXPEJ; ISSN: 1046-5928

PB Elsevier Science

DT Journal

LA English

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 3

AB The Tol/Pal system of Escherichia coli is composed of the YbgC, TolQ, TolA, TolR, TolB, Pal and YbgF proteins. It is involved in maintaining the integrity of the outer membrane, and is required for the uptake of group A colicins and DNA of filamentous bacteriophages. To identify new interactions between the components of the Tol/Pal system and gain insight into the mechanism of colicin import, we performed a yeast two-hybrid screen using the different components of the Tol/Pal system and colicin A. Using this system, we confirmed the already known interactions and identified several new interactions. TolB dimerizes and the periplasmic domain of TolA interacts with YbgF and TolB. Our results indicate that the central domain of TolA (TolAII) is sufficient to interact with YbgF, that the C-terminal domain of TolA (TolAIII) is sufficient to interact with TolB, and that the amino terminal domain of TolB (D1) is sufficient to bind TolAIII. The TolA/TolB interaction was confirmed by cross-linking experiments on purified proteins. Moreover, we

show that the interaction between TolA and TolB is required for the uptake of colicin A and for the membrane integrity. These results demonstrate that the TolA/TolB interaction allows the formation of a trans-envelope complex that brings the inner and outer membranes in close proximity.

AN 2002255270 MEDLINE
DN PubMed ID: 11994151
TI The Tol/Pal system function requires an interaction between the C-terminal domain of TolA and the N-terminal domain of TolB.
AU Walburger Anne; Lazdunski Claude; Corda Yves
CS Laboratoire d'Ingenierie des Systemes Macromoleculaires, Institut de Biologie Structurale et Microbiologie, CNRS 31, Chemin Joseph Aiguier, Marseille, France.
SO Molecular microbiology, (2002 May) Vol. 44, No. 3, pp. 695-708.
Journal code: 8712028. ISSN: 0950-382X.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200207
ED Entered STN: 8 May 2002
Last Updated on STN: 23 Jul 2002
Entered Medline: 22 Jul 2002

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4
AB Overprod. of the third topol. domain of the transmembrane protein TolA (TolAIII) in the periplasm of Escherichia coli confers a "leaky" phenotype to host cells by disrupting the integrity of the outer membrane and causing periplasmic proteins to leach into the growth medium. To examine the physiol. consequences of TolAIII overexpression in more detail and assess the usefulness of this strategy for the release of periplasmic recombinant proteins into the extracellular fluid, we constructed a ColE1-compatible plasmid encoding a fusion between the ribose binding protein signal sequence and TolAIII under T7lac transcriptional control. About half of the total TolAIII synthesized in IPTG-induced cells aggregated in a precursor form in the cytoplasm. However, the majority of the mature protein was soluble and located in the extracellular fluid. TolAIII-overproducing cultures exhibited only slight growth defects upon entry into stationary phase but underwent extensive lysis when treated with 0.1% (w/v) SDS, and were unable to divide when supplemented with 0.02% SDS. The loss of outer membrane integrity resulted in longterm damage since cell viability was reduced by three orders of magnitude compared to control or uninduced cells. Overexpression of TolAIII did not significantly interfere with the translocation and processing of a plasmid-encoded fusion between the OmpA signal sequence and TEM- β -lactamase but led to the release of most periplasmic proteins and 90% of the active enzyme into the extracellular fluid. Although the total levels of β -lactamase accumulation in TolAIII-overproducing cultures was only 1.5- to 2-fold less than in control cells, the formation of periplasmic inclusions bodies was completely suppressed. A threshold concentration of TolAIII was necessary for efficient release of periplasmic proteins since the viability and detergent sensitivity of uninduced cells was comparable to that of control cultures and 80% of the β -lactamase synthesized remained confined to the periplasm. (c) 1998 Academic Press.

AN 1998:671728 CAPLUS
DN 130:33638
TI TolAIII co-overexpression facilitates the recovery of periplasmic recombinant proteins into the growth medium of Escherichia coli
AU Wan, Eugene W.-M.; Baneyx, Francois
CS Department of Chemical Engineering, University of Washington, Seattle, WA, 98195, USA
SO Protein Expression and Purification (1998), 14(1), 13-22

CODEN: PEXPEJ; ISSN: 1046-5928
PB Academic Press
DT Journal
LA English

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT